Poland
· Delayed Price · Currency is PLN Genomed Spólka Akcyjna Statistics
Total Valuation
Genomed Spólka Akcyjna has a market cap or net worth of PLN 37.00 million. The enterprise value is 33.76 million.
| Market Cap | 37.00M |
| Enterprise Value | 33.76M |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomed Spólka Akcyjna has 1.32 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 1.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 44.76% |
| Owned by Institutions (%) | n/a |
| Float | 41,650 |
Valuation Ratios
The trailing PE ratio is 42.18.
| PE Ratio | 42.18 |
| Forward PE | n/a |
| PS Ratio | 1.60 |
| PB Ratio | 3.84 |
| P/TBV Ratio | 3.88 |
| P/FCF Ratio | 439.79 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.22, with an EV/FCF ratio of 401.32.
| EV / Earnings | 38.49 |
| EV / Sales | 1.46 |
| EV / EBITDA | 18.22 |
| EV / EBIT | 28.60 |
| EV / FCF | 401.32 |
Financial Position
The company has a current ratio of 7.79
| Current Ratio | 7.79 |
| Quick Ratio | 5.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 2,389.83 |
Financial Efficiency
Return on equity (ROE) is 9.55% and return on invested capital (ROIC) is 8.03%.
| Return on Equity (ROE) | 9.55% |
| Return on Assets (ROA) | 7.17% |
| Return on Invested Capital (ROIC) | 8.03% |
| Return on Capital Employed (ROCE) | 11.88% |
| Revenue Per Employee | 480,497 |
| Profits Per Employee | 18,275 |
| Employee Count | 44 |
| Asset Turnover | 2.24 |
| Inventory Turnover | 4.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.50% in the last 52 weeks. The beta is -0.02, so Genomed Spólka Akcyjna's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -8.50% |
| 50-Day Moving Average | 27.19 |
| 200-Day Moving Average | 30.18 |
| Relative Strength Index (RSI) | 57.75 |
| Average Volume (20 Days) | 35 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomed Spólka Akcyjna had revenue of PLN 23.06 million and earned 877,195 in profits. Earnings per share was 0.66.
| Revenue | 23.06M |
| Gross Profit | 14.53M |
| Operating Income | 1.18M |
| Pretax Income | 1.00M |
| Net Income | 877,195 |
| EBITDA | 1.85M |
| EBIT | 1.18M |
| Earnings Per Share (EPS) | 0.66 |
Balance Sheet
| Cash & Cash Equivalents | 3.24M |
| Total Debt | n/a |
| Net Cash | 3.24M |
| Net Cash Per Share | 2.45 |
| Equity (Book Value) | 9.63M |
| Book Value Per Share | 7.28 |
| Working Capital | 6.14M |
Cash Flow
In the last 12 months, operating cash flow was 1.83 million and capital expenditures -1.75 million, giving a free cash flow of 84,122.
| Operating Cash Flow | 1.83M |
| Capital Expenditures | -1.75M |
| Free Cash Flow | 84,122 |
| FCF Per Share | 0.06 |
Margins
Gross margin is 62.98%, with operating and profit margins of 5.12% and 3.80%.
| Gross Margin | 62.98% |
| Operating Margin | 5.12% |
| Pretax Margin | 4.35% |
| Profit Margin | 3.80% |
| EBITDA Margin | 8.03% |
| EBIT Margin | 5.12% |
| FCF Margin | 0.36% |
Dividends & Yields
Genomed Spólka Akcyjna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.37% |
| FCF Yield | 0.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomed Spólka Akcyjna has an Altman Z-Score of 22.81.
| Altman Z-Score | 22.81 |
| Piotroski F-Score | n/a |